Short-term supplementation of EPA-enriched ethanolamine plasmalogen increases the level of DHA in the brain and liver of n-3 PUFA deficient mice in early life after weaning

Fu, Shuai; Wen, Min; Zhao, Yang; Shi, Hao‐Hao; Xue, Changhu; Wang, Yuming; Wei, Zihao; Zhang, Tiantian

doi:10.1039/d1fo03345j

Cited by 9 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a previous study reported that both EPA and DHA indiscriminately exhibited anti-ageing effects by antioxidation and reducing ageing-related proteins [23]. Since EPA supplementation or its derivatives could significantly increase the amount of EPA and DHA in the brain [24,25], EPA's effect may partly depend on DHA function. The PUFAs profile in our study showed that both EPA and DHA treatments respectively reversed the decrease of EPA or DHA in ageing rats' brains, which was more conducive to revealing their commonalities and specific mechanisms for improving ageing-related memory impairment.…”

Section: Discussionmentioning

confidence: 98%

Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid or Docosahexaenoic Acid Improved Ageing-Associated Cognitive Decline by Regulating Glial Polarization

et al. 2023

View full text Add to dashboard Cite

Neuroinflammation induced by microglial and astrocyte polarizations may contribute to neurodegeneration and cognitive impairment. Omega (n)-3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory and neuroprotective effects, but conflicting results were reported after different n-3 PUFA treatments. This study examined both the change in glial polarizations in ageing rats and the differential effects of two omega-3 PUFAs. The results showed that both PUFAs improved spatial memory in ageing rats, with docosahexaenoic acid (DHA) being more effective than eicosapentaenoic acid (EPA). The imbalance between microglial M1/M2 polarizations, such as up-regulating IBA1 and down-regulating CD206 and arginase-1 (ARG-1) was reversed in the hippocampus by both n-3 PUFAs, while the DHA effect on CD206 was stronger. Astrocyte A1 polarization presented increasing S100B and C3 but decreasing A2 parameter S100a10 in the ageing brain, which were restored by both PUFAs, while DHA was more effective on S100a10 than EPA. Consistent with microglial M1 activation, the concentration of proinflammatory cytokines tumor necrosis factor-(TNF) α, interleukin (IL)-1β and IL-6 were significantly increased, which were attenuated by DHA, while EPA only suppressed IL-6. In correlation with astrocyte changes, brain-derived neurotrophic factor precursor was increased in ageing rats, which was more powerfully down-regulated by DHA than EPA. In summary, enhanced microglial M1 and astrocytic A1 polarizations may contribute to increased brain proinflammatory cytokines, while DHA was more powerful than EPA to alleviate ageing-associated neuroimmunological changes, thereby better-improving memory impairment.

show abstract

Section: Discussionmentioning

confidence: 98%

Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid or Docosahexaenoic Acid Improved Ageing-Associated Cognitive Decline by Regulating Glial Polarization

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In terms of human diet and health benefits, LC-PUFA-containing phospholipids may have more health benefits through alternate uptake mechanisms and can cross the blood-brain barrier [44]. Plasmalogen PE species with EPA have been shown to efficiently increase brain omega-3 PUFA concentration [45]. The phospholipid PUFA species have been shown to be quickly taken up in the brain and other tissues where PUFA deficiency is occurring.…”

Section: Discussionmentioning

confidence: 99%

A Lipidomic Profile of a Sustainable Source of Omega-3 Long-Chain Polyunsaturated Fatty Acids, Greenshell Mussels™, Perna canaliculus

Taylor

Roberts²,

Miller

2023

Sustainability

View full text Add to dashboard Cite

Greenshell mussel (GSM- Perna canaliculus) is the most important aquaculture species in New Zealand and produces one of the most expensive bioactive lipid extracts on the nutraceutical market. There have been numerous studies on the composition of GSM as well as pre-clinical and clinical studies on the efficacy of GSM extracts and foods. With increases in analytical capabilities, lipidomic studies using advanced mass spectral data may provide new insight into the content and activity of the lipidome, the totality of all lipids, of GSM. This study is the first reported characterisation of the GSM lipidome which may disclose important novel information regarding its nutrition, biology, physiology, and epidemiology. This study adds to the traditional lipid analytical outputs with new lipidomic capabilities to interrogate the lipid species differences between tissues rich in oil. We have identified 16 different lipid species in GSM including ceramide aminoethyl phosphonate (CAEP). Many lipid species are differentially expressed between tissues and correlation analysis demonstrates lipid species associated with the digestive gland that may be obtained from food sources, whilst other lipid species are dominant in the mantle or gonad. Linking this new information to the GSM breeding programmes may deliver functional breeding attributes to deliver premium strains for enhanced nutrition and/or extract production.

show abstract

Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen‐Based Nanomedicines

Wu,

Wang,

Deng

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Plasmalogens (vinyl‐ether phospholipids) are an emergent class of lipid drugs against various diseases involving neuro‐inflammation, oxidative stress, mitochondrial dysfunction, and altered lipid metabolism. They can activate neurotrophic and neuroprotective signaling pathways but low bioavailabilities limit their efficiency in curing neurodegeneration. Here we created liquid crystalline lipid nanoparticles (LNPs) for protection and non‐invasive intranasal delivery of purified scallop‐derived plasmalogens. Our in vivo results with a transgenic mouse Parkinson's disease (PD) model (characterized by motor impairments and α‐synuclein deposition) demonstrated the crucial importance of LNP composition, which determines the self‐assembled nanostructure type. Vesicle and hexosome nanostructures (characterized by SAXS) displayed different efficacy of the nanomedicine‐mediated recovery of motor function, lipid balance, and transcriptional regulation (e.g., reduced neuro‐inflammation and PD pathogenic gene expression). Intranasal vesicular and hexosomal plasmalogen‐based LNP treatment led to improvement of the behavioral PD symptoms and downregulation of the Il6, Il33, and Tnfa genes. Moreover, RNA‐sequencing and lipidomic analyses established a dramatic effect of hexosomal nanomedicines on PD amelioration, lipid metabolism, and the type and number of responsive transcripts that may be implicated in neuroregeneration.This article is protected by copyright. All rights reserved

show abstract

Short-term supplementation of EPA-enriched ethanolamine plasmalogen increases the level of DHA in the brain and liver of n-3 PUFA deficient mice in early life after weaning

Abstract: The lack of n-3 polyunsaturated fatty acids (PUFAs) in the mother's diet significantly reduced the amount of docosahexaenoic acid (DHA) in the brains of offspring, which might affect their brain...

Cited by 9 publications

References 48 publications

Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid or Docosahexaenoic Acid Improved Ageing-Associated Cognitive Decline by Regulating Glial Polarization

Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid or Docosahexaenoic Acid Improved Ageing-Associated Cognitive Decline by Regulating Glial Polarization

A Lipidomic Profile of a Sustainable Source of Omega-3 Long-Chain Polyunsaturated Fatty Acids, Greenshell Mussels™, Perna canaliculus

Lipid and Transcriptional Regulation in a Parkinson's Disease Mouse Model by Intranasal Vesicular and Hexosomal Plasmalogen‐Based Nanomedicines

Contact Info

Product

Resources

About